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Abstract Basic fibroblast growth factor (bFGF) stimulated
[3H]thymidine incorporation at all stages of development,
although the magnitude of this effect was the greatest in cells
derived from pregnant mice. Cells primed with insulin and bFGF
synthesized more casein than cells not exposed to either hormone.
bFGF inhibited casein synthesis and decreased the amounts of
L-casein and K-lactalbumin transcripts in cells from pregnant
animals simultaneously incubated with insulin, hydrocortisone
and prolactin. bFGF content in mammary gland increased with
puberty and pregnancy, but decreased markedly in lactation; the
number of bFGF receptors in epithelial cells changed in parallel.
These data suggest that bFGF may have a physiological role both
in stimulating growth and in inhibiting functional differentiation
of normal mouse mammary epithelial cells.
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1. Introduction
The process whereby embryonic mouse mammary epithelial
cells (MMEC) develop into secretory cells capable of produc-
ing milk involves a series of growth and developmental
changes that occur over a relatively long period of time.
The mammary tissue of virgin animals is developmentally
dormant and it contains a relatively small number of epithelial
cells. During pregnancy, MMEC multiply extensively to form
the lobulo-alveolar structure, although their ability to produce
milk still is suppressed. Following parturition, the mammary
tissue expresses its di¡erentiated function by synthesizing and
secreting milk and then regresses to the undi¡erentiated states
upon weaning [1]. Mouse mammary growth and di¡erentia-
tion that occur during pregnancy and lactation are controlled
by systemic steroid and polypeptide hormones as well as local
regulatory growth factors [2]. Although the importance of
endocrine hormones such as estrogen, progesterone, prolactin
and growth hormone in the mammary gland has been well
documented, these hormones are virtually incapable of stim-
ulating mammary epithelial cell growth in vitro [3]. Thus, the
growth stimuli for mammary cells need clari¢cation. In recent
years, epidermal growth factor (EGF), insulin-like growth fac-
tor-I, transforming growth factor K and L have been impli-
cated in mammary gland development [2,4]. Basic ¢broblast
growth factor (bFGF or FGF-2) is a member of a large multi-
gene family of heparin-binding growth factors [5^7], which
can act locally in a paracrine, autocrine or intracrine fashion
[8]. Although originally described as a mitogen for ¢broblasts,
bFGF is also a potent mitogen agent for diverse cell types [9].
Some studies have indicated the presence of bFGF in the
mammary tissue [10^14]. Northern blot analysis has revealed
three bFGF mRNA transcripts of 7.5, 4.4, and 2.2 kb in
human mammary epithelial cells (HMEC) and in the immor-
tal mammary cell line HBL-100 [10]. However, of the four
mammary-tumor-derived cell lines, only the Hs578T cells pro-
duced detectable levels of bFGF mRNA. Western blot anal-
ysis of cell lysates using an anti-bFGF monoclonal antibody
detected three distinct molecular weight species of bFGF pro-
tein (18, 24 and 27 kDa) in normal HMEC strains, in HBL-
100 and HS578T cells, but not in the other tumor cell lines
[10]. FGF-1 (acidic ¢broblast growth factor or aFGF), FGF-
2, FGF-4 and FGF-7 are expressed during the ductal stage of
mammary development, the majority of FGF-1 gene expres-
sion was in the luminal epithelial cells, whereas FGF-2 ex-
pression was in the mammary stroma and possibly the myoe-
pithelial cells [13]. Several lines of evidence suggest a role for
bFGF in the growth and di¡erentiation of the mammary
gland. bFGF stimulates the growth of rat mammary myoepi-
thelial and stromal cell lines in culture [15], mammary epithe-
lial cell line COMMDA-1D [16] and also T-47 and MCF7
breast cancer cells [17,18]. bFGF also stimulates growth and
inhibits casein production in virgin mouse mammary cells [19].
These ¢ndings prompted us to examine the e¡ect of bFGF on
proliferation and milk protein gene expression in normal
MMEC di¡erentiating in culture and to study the changes
in the content of bFGF and the number of bFGF receptors
in these cells during the development of the mouse mammary
gland.
2. Materials and methods
2.1. Chemicals
Sources were as follows: protosol and [3H]amino-acid mixture
(1 mCi/ml), NEN-Dupont (Boston, MA, USA; [methyl-3H]thymidine
(68 Ci/mmol) and [K-32P]UTP (800 Ci/mmol), Amersham (Arlington
Heights, IL, USA); Na125I, ComisioŁn Chilena de Energ|Ła Nuclear
(Santiago, Chile); Riboprobe system, Promega (Madison, WI,
USA); T7 and T3 RNA polymerases, Stratagene (La Jolla, CA,
USA); human recombinant bFGF, Chiron (Emeryville, CA, USA);
mouse EGF (culture grade), Collaborative Research (Bedford, MA,
USA); goat-anti-rabbit IgG, Miles Lab. (Elkhart, IN, USA); A⁄-Gel
heparin gel (90^180 Wm), Bio-Rad (CA, USA); Vitrogen 100 (puri¢ed
collagen), Celtrix Pharmaceuticals (Santa Barbara, CA, USA); DME
and fetal bovine serum medium, Gibco (Grand Island, NY, USA);
FEBS 21124 20-11-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 1 3 7 0 - 2
*Corresponding author. Fax: (56) (2) 737-8920.
E-mail: slavande@ll.ciq.uchile.cl
Abbreviations: bFGF, basic fibroblast growth factor; EGF, epidermal
growth factor ; F, hydrocortisone ; I, insulin ; MMEC, mouse
mammary epithelial cells ; P, prolactin
FEBS 21124 FEBS Letters 439 (1998) 351^356
collagenase (CLS III, 118^120 U/mg), Worthington (Freehold, NJ,
USA); hydrocortisone, Calbiochem (San Diego, CA, USA). Crystal-
line porcine zinc insulin was a gift from Eli Lilly (Indianapolis, IN,
USA). Ovine prolactin (NIDD-oPRL 19) was obtained from the
Hormone Distribution Program, NIDDK, NIH. HEPES, bicin-
choninic acid, heparin, Nonidet P-40, leupeptin, CHAPS, gelatin,
SDS, PMSF, anti-rabbit IgG (made in goats, a⁄nity puri¢ed), re-
agents for SDS-PAGE and Western blot, polyclonal anti-bFGF anti-
body against human recombinant bFGF, Sigma (St. Louis, MO,
USA).
2.2. Animals
C3H/HeN mice in di¡erent physiological states (virgin, pregnant
and lactating), were obtained from the Animal Breeding Facility of
the University of Chile. Day 0 of pregnancy was the day in which a
vaginal plug was observed, and the day of parturition was counted as
day 0 of lactation.
2.3. Primary mammary cell culture
MMEC from female mice at di¡erent stages of the lactogenic cycle
(virginity, pregnancy and lactation) were isolated and cultured as
previously described [20]. Microscopic analysis revealed that MMEC
comprised over 95% of the total population. The remaining cells (¢-
broblasts, endothelial and myoepithelial cells) were estimated to be
less than 5% of the total cell population in agreement with our pre-
vious study [20]. Since myoepithelial cells were a minority component
in our cell system, our ¢ndings described here on proliferation, milk
protein gene expression, bFGF receptors and bFGF content corre-
spond to the mammary epithelial cell component. The concentrations
of hormones and growth factors were: insulin (I), 5 Wg/ml; prolactin
(P), 5 Wg/ml; hydrocortisone (F), 1 Wg/ml; EGF, 10 ng/ml; and
bFGF, 5 ng/ml, unless stated otherwise. For studies of cell prolifer-
ation, cells were cultured for 3 days. For cell di¡erentiation, cells were
primed with bFGF for 2 days to stimulate cell proliferation, washed
4 times in medium without hormones and were then induced to di¡er-
entiate for 3 days in the presence of IFP.
2.4. DNA synthesis
DNA synthesis was determined by the incorporation of
[3H]thymidine (0.1 WCi/ml) into trichloroacetic acid (TCA)-insoluble
material [10].
2.5. Casein and total protein synthesis
Casein synthesis was determined by incubation of MMEC in the
presence of 3H-amino acid mixture (10 WCi/ml), unless noted other-
wise. After 24 h, culture medium was collected and used for the
determination of labeled casein which had been secreted. Cells were
homogenized with 1.5 ml PBS solution containing 1% (w/v) Triton X-
100. The homogenate was centrifuged at 105 000Ug for 60 min and
the resultant supernatant was used for the determination of intracel-
lular casein synthesis. Radiolabeled casein was separated by indirect
immunoprecipitation using rabbit IgG anti-mouse casein antiserum
and goat anti-rabbit IgG antiserum [21]. Total casein synthesis was
obtained by combining the values for the secreted and intracellular
caseins. Total secreted protein was assessed from the incorporation of
3H-amino acid into TCA-insoluble material [21]. Both casein and
total protein synthesis increases were almost completely inhibited by
cycloheximide in MMEC obtained from pregnant mammary tissue,
discarding that this increase was due to an enhanced intracellular
speci¢c activity of the precursor pools.
2.6. Milk protein mRNA expression
Total cellular RNA was extracted from mammary cells as previ-
ously described [22]. The RNA concentration was determined by its
absorbance at 260 nm. Dot blot analysis were performed as previously
described [22]. Radiolabeled riboprobes complementary to mouse L-
casein and mouse K-lactalbumin mRNA, respectively, were used as
hybridization probes. [32P]Casein riboprobe was synthesized from the
cDNA cloned into pBS(3) plasmid vector using T7 RNA polymerase
and [K-32P]UTP according to the manufacturer’s protocol. The la-
beled riboprobe corresponds to the portion of mouse L-casein
cDNA between bases 278 and 930 [23]. Mouse K-lactalbumin
cDNA, originally cloned in plasmid pBR 322, was recloned into the
pBS(3) vector; an [K-32P]lactalbumin riboprobe was synthesized as
above. Although normalization to a constitutively expressed mRNA
such as actin or GAPDH is often done, this may not be too informa-
tive because the levels of these mRNA also change, depending on the
developmental stage of mammary gland. Data were expressed on the
basis of total RNA.
2.7. bFGF radioimmunoassay and Western blot analysis
For quantitation of bFGF we used human recombinant [125I]bFGF
as a ligand and a polyclonal anti-bFGF antibody against human
recombinant bFGF as the binder. bFGF was labeled with 125I accord-
ing to the chloramine-T method [24]. After that, the procedure follows
the one published for the bFGF RIA [25]. Each mammary sample
was analyzed separately, weighed and mixed with 4 vol. of cold 0.4 M
NaCl in 50 mM Tris-HCl, pH 7.4, with 10 mM MgCl2, 1% Nonidet
P-40, 1 mM PMSF, 1 Wg/ml leupeptin. The tissue was then brie£y
homogenized by Ultraturrax and centrifuged at 12 000Ug for 10 min
at 4‡C. The supernatant was absorbed at 4‡C overnight (with gentle
rocking) to swollen heparin-Sepharose (1 ml per 10 g of wet tissue)
equilibrated with 0.6 M NaCl, 0.2% gelatin, 0.02% CHAPS and
20 mM NaH2PO4 (pH 7.4). The non-adsorbed supernatant was dec-
anted by centrifugation for 8 min at 6000Ug and the beads were
poured into a column and washed with 20 column vol. of 0.6 M
NaCl, 0.2% gelatin, 0.02% CHAPS and 20 mM NaH2PO4 (pH 7.4).
The column was then eluted with 0.6 ml fractions of 2 M NaCl, 0.2%
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Table 1
E¡ect of bFGF and EGF on thymidine incorporation of cultured MMEC at di¡erent physiological states
Physiological state [3H]Thymidine incorporation (cpm/dish/24 h)U1035
Control bFGF EGF
Virginity 1.09 þ 0.06 1.68 þ 0.15** 1.63 þ 0.09*
Pregnancy 0.61 þ 0.01 2.07 þ 0.17** 1.48 þ 0.06**
Lactation 0.48 þ 0.04 0.79 þ 0.12 1.15 þ 0.12*
MMEC from virgin (3 months old), pregnant (18 days) or lactating (8 days) mice were plated at the same starting cell density and cultured for
2 days in medium alone or either 5 ng/ml bFGF or 10 ng/ml EGF. Medium was changed daily and on the last day of incubation cells were pulsed
with 1 WCi/ml [3H]thymidine. Each point represents the mean þ S.E.M. (n=3). *P6 0.05 and **P6 0.01 are signi¢cantly di¡erent from cells
incubated with medium alone.
Table 2
E¡ect of bFGF on casein secretion to the culture medium, intracel-
lular casein and total amount of casein in a two-step culture mam-
mary system
Condition L-Casein (cpm per cell culture system/24 hU1033)
Intracellular Extracellular Total
Control 2.7 þ 0.3 5.4 þ 1.0 8.1 þ 1.4
I 21.1 þ 1.9**;# 43.2 þ 1.5**;# 64.2 þ 3.4**;#
bFGF 7.6 þ 0.8*;# 9.1 þ 0.4# 16.8 þ 1.2*;#
I+bFGF 31.0 þ 0.9** 56.9 þ 1.1** 87.9 þ 2.0**
MMEC from mid-pregnant mice were cultured with the medium
alone or containing I (5 Wg/ml), bFGF (5 ng/ml) or both in the ¢rst
incubation period (2 days) and further cultured with IFP and 3H-
amino acid mixture (10 WCi/ml) in the second incubation period
(2 days). Casein secreted to culture medium and intracellular casein
were determined by immunoprecipitation. Total casein was obtained
by adding intracellular and secreted casein. Values are the mean þ
S.E.M. (n = 4). *P6 0.05 and **P6 0.01 vs. control; #P6 0.001 vs.
I+bFGF.
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gelatin, 0.02% CHAPS and 20 mM NaH2PO4 (pH 7.4). The fractions
were collected in polypropylene tubes and frozen at 380‡C.
For bFGF Western blot analysis the proteins binding to the hep-
arin-Sepharose beads were eluted by boiling the beads for 5 min in
2U SDS-PAGE sample bu¡er (0.125 M Tris, pH 6.8; 4% SDS, 20%
glycerol and 200 mM dithiothreitol). The samples were then analyzed
by 15% SDS-PAGE and the separated proteins were blotted to a
nitrocellulose membrane. The Western blots were blocked with 5%
(w/v) non-fat powdered milk in PBS; washed three times with PBS-
0.05% Tween 20 and incubated sequentially with a polyclonal anti-
bFGF antibody and anti-rabbit IgG (made in goats, a⁄nity puri¢ed
and labeled with 125I). Then nitrocellulose sheets were washed three
times, dried and exposed for radioautography at 370‡C with intensi-
¢er screens.
2.8. FGF binding assays
The binding of [125I]bFGF to MMEC was performed as described
previously [26]. MMEC (1^10U106 cells) were incubated with
[125I]bFGF (1.5^2.5U104 cpm) and increasing concentrations of
bFGF in 250 Wl of HEPES binding bu¡er (100 mM HEPES, pH
7.4; 150 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 8.8 mM dextrose,
0.05% gelatin and heparin 0.3 Wg/ml) at 4‡C for 18 h. At the end of
incubation, the cells were washed (3U1 ml) with cold PBS followed by
an extraction with 20 mM HEPES containing 2 M NaCl (1U1 ml).
Subsequently, the cells were lysed with 0.5% SDS (2U250 Wl), and
radioactivity in the NaCl and SDS extracts was measured in a Pack-
ard Q-counter. Bound cpm were normalized according to protein con-
tent of SDS extracts as measured by bicinchoninic acid protein assay
[27].
2.9. Statistics
Data were analyzed by a statistic computer program (GB-STD
version 3.0, USA). An ANOVA test followed of the Tukey’s protected
t-test were used to analyze the heterogeneity of the experimental
groups and to set signi¢cance of paired values with a value of
P6 0.05.
3. Results
3.1. The e¡ect of bFGF concentration on the growth of primary
MMEC in culture
As measured by incorporation of [3H]thymidine into DNA,
both human and bovine recombinant bFGF stimulated pro-
liferation of primary MMEC from pregnant mice in culture
with similar kinetics (data not shown). The maximal stimula-
tion was observed at 5 ng/ml bFGF with ED50 values of
approximately 0.5 ng/ml in mouse pregnant mammary epithe-
lial cells. The addition of cytarabine, a well known DNA syn-
thesis inhibitor, to the medium of the cultured MMEC
showed that [3H]thymidine incorporation was signi¢cantly in-
hibited (s 85%) in the presence or absence of the growth
factor. This control rules out that an increased [3H]thymidine
incorporation is due to an increased uptake by MMEC. In
addition to the increase in DNA synthesis as measured by
[3H]thymidine incorporation there was an increase in cell
number as observed microscopically or by counting. As
shown in Table 1, bFGF (5 ng/ml) stimulated growth of
MMEC from virgin, pregnant and lactating mammary glands
(P6 0.05); the magnitude of the stimulatory e¡ect was largest
on cells derived from pregnant mice. As shown previously
[20], mammary cell proliferation was also stimulated by
EGF but to a lesser extent than with bFGF in cells from
pregnant animals.
3.2. bFGF action on mammary cell di¡erentiation in vitro
MMEC were primed with insulin and growth factors to
stimulate proliferation and were then induced to di¡erentiate
by further incubation with insulin, hydrocortisone and prolac-
tin [22]. This two-step culture system simulates the stages of
proliferation and di¡erentiation in the mammary gland during
pregnancy and lactation, respectively. As shown in Table 2,
cells primed with insulin and bFGF together produced a
greater amount (about 11 times) of casein than those not
primed. This was true for both secreted and intracellular ca-
sein. The e¡ects of insulin and bFGF were additive, paralle-
ling the relative stimulation of cell proliferation by the two
factors in single cultures (results not shown). Cells primed
with insulin and bFGF also showed a 4-fold increase in the
synthesis of total proteins relative to controls (results not
shown). Table 3 shows that the amounts of L-casein and K-
lactalbumin mRNAs (relative to the appropriate controls)
were also increased substantially by insulin and bFGF, indi-
cating that at least part of the increase in milk protein syn-
thesis is regulated at the level of transcription. MMEC pro-
duce milk proteins (albeit to a limited extent, as shown in
Table 2) in response to IFP in a one-step culture system.
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Table 3
E¡ect of bFGF in L-casein and K-lactalbumin transcript induction on two step culture
1st incubation 2nd incubation Relative amounts of transcripts
L-Casein K-Lactalbumin
None IFP 100 þ 8 100 þ 7
I IFP 300 þ 8**;# 147 þ 7**;#
bFGF IFP 182 þ 6**;# 137 þ 3**;#
I+bFGF IFP 338 þ 10** 170 þ 8**
MMEC were cultured with the indicated agents in the ¢rst incubation period (2 days) and further cultured with IFP in the second incubation period
(2 days). After the last incubation period, total cellular RNA was extracted and the amount of L-casein and K-lactalbumin transcripts was examined
by dot blot hybridization. The amount of L-casein and K-lactalbumin transcripts in cultured tissue was assigned the value 100. Values are the
mean þ S.E.M. (n = 6). **P6 0.01 signi¢cantly di¡erent from control; #P6 0.01 signi¢cantly di¡erent from I+bFGF.
Table 4
E¡ect of bFGF on the synthesis of casein in cultured MMEC
bFGF (ng/ml) IFP Casein (cpm per cell culture system/24
hU1033)
0 + 1.40 þ 0.11
0.1 + 1.47 þ 0.10
0.5 + 1.26 þ 0.09
1 + 0.54 þ 0.09*
5 + 0.54 þ 0.07*
10 + 0.62 þ 0.05*
50 + 0.55 þ 0.07*
Mammary cells from late pregnant mice were cultured for 3 days in
medium alone (NH) or containing IFP and the indicated concentra-
tion of bFGF. Labeled amino acid mixture (10 WCi/ml) was added to
the medium after a 24-h plating period and was present throughout
the culture period. At the end of incubation the amount of [3H]casein
presented in the medium was determined by immunoprecipitation.
Each point represents the average þ S.E.M. (n = 3). *Signi¢cantly dif-
ferent from those cells cultured without bFGF (P6 0.01).
S. Lavandero et al./FEBS Letters 439 (1998) 351^356 353
When bFGF is added to such cultures, casein production is
decreased in a dose-dependent manner (Table 4) and maxi-
mally by 63% (P6 0.001). In the same single incubation cul-
ture system, casein and K-lactalbumin gene expression was
also substantially decreased by bFGF (Fig. 1).
3.3. Content and receptor density of bFGF in the mammary
tissue
The content of bFGF in mammary tissue changes markedly
during development and in lactation, rising at puberty and
again in early pregnancy. From mid-pregnancy onwards and
during lactation, the content falls to the pre-pubertal level.
These variations are re£ected in parallel changes in the num-
ber of bFGF receptors in MMEC from animals at the same
stages of development (Table 5).
The results of Western blot analysis using a polyclonal anti-
bFGF antibody showed that bFGF proteins were identi¢ed in
the extracts of the mammary tissue. Bands were seen at 18, 26
and 45 kDa in the mid-pregnant tissue, the 18-kDa bFGF
species being predominant (s 90%). A lower amount of
bFGF proteins was observed in the lactating mammary tissue
and the 18-kDa band was not detected. The 26- and 45-kDa
forms were present in similar abundance in the lactating mam-
mary tissue.
4. Discussion
An increasing body of evidence has indicated that growth
factors may play an important role in the control of mam-
mary cell growth and di¡erentiation [2^4]. Such growth fac-
tors may be synthesized locally or originate in other tissues.
Studies both in vitro and in vivo have demonstrated the im-
portance of EGF [20,21], insulin-like growth factor-1 [28,29]
and transforming growth factors [30,31] in the development of
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Fig. 1. E¡ect of bFGF on milk protein gene expression. MMEC from pregnant mice were cultured for 2 days with incubation medium alone
(N), insulin (I; 5 Wg/ml), bFGF (5 ng/ml), IFP or containing IFP and bFGF (5 ng/ml). Total cellular RNA was extracted, dotted on a nitrocel-
lulose membrane, hybridized with L-casein or K-lactalbumin riboprobes, respectively, and the extent of hybridization was determined. The
amount of transcripts in uncultured tissue was assigned the value 100. Values are the average þ S.E.M. (n = 3). **P6 0.01, signi¢cantly di¡erent
from control (N); #P6 0.05 and ##P6 0.01 vs. IFP+bFGF.
Table 5
Content of bFGF and receptor density of bFGF during the development of the mammary tissue
Stage n Mammary weight (g) bFGF mammary content (ng/g) FGF receptor density (fmol/mg
protein)
Virginity
Prepuberty 6 0.20 þ 0.04 62 þ 11 ND
Puberty 6 0.47 þ 0.09** 192 þ 45** 6 þ 3 (n = 3)
Pregnancy
Early 4 0.74 þ 0.10** 185 þ 22** ND
Middle 5 0.90 þ 0.09** 260 þ 10** 27 þ 10* (n = 3)
Late 5 0.88 þ 0.12** 58 þ 12 ND
Lactation
Middle 6 1.45 þ 0.28** 41 þ 5 12 þ 4 (n = 3)
Post-lactation 6 0.76 þ 0.16** 105 þ 20 ND
Female mice at di¡erent stages of the lactogenic cycle (prepuberty, 3^4 weeks; puberty, 8 weeks; early pregnancy, 7 days gestation; middle
pregnancy, 8^15 days gestation; late pregnancy, 16^20 days gestation; middle lactation, 10^12 days post-parturition; post-lactation, 15^20 days
weaning) were sacri¢ced and abdominal and thoracic mammary gland were excised and weighed. The bFGF mammary content was determined by
RIA as described in Section 2. In other experimental groups, the number of high a⁄nity FGF binding sites was determined in plasma membranes
obtained from MMEC as also described in Section 2. Values are the mean þ S.E.M; n = number of animals; ND: not done. *P6 0.05 and
**Ps 0.01 are signi¢cantly di¡erent from prepuberal animals.
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the mammary gland. Our identi¢cation of a mesenchyme-de-
rived growth factor, with similarities to members of the hep-
arin-binding growth factor family, which a¡ects growth and
di¡erentiation of MMEC [32], led us also to investigate the
presence of bFGF, the changes in its content and their recep-
tors as well as the e¡ect of bFGF on the development of this
tissue.
The immunological studies con¢rmed the presence of bFGF
in the mammary tissue as previously reported [10^13]. Other
studies have shown that bFGF was found to be predomi-
nantly associated to MMEC ([10], Lavandero et al., unpub-
lished data). bFGF has been immunocytochemically detected
in the basement membrane of the human breast, and may
arise from the myoepithelial cells of the mammary parenchy-
ma [33]. However, other studies have reported that the ma-
jority of FGF-1 (aFGF) gene expression was in the luminal
epithelial cells, whereas bFGF expression was in the mam-
mary stroma and possibly the myoepithelial cells [13,34]. We
have detected the presence of aFGF in the myoepithelial cells
(Lavandero et al., unpublished data). The presence of bFGF
protein in the mouse mammary tissue extracts was con¢rmed
by Western blot analysis using an anti-bFGF polyclonal anti-
body, which showed three distinct molecular weight species of
bFGF protein (18, 26 and 45 kDa). The 18-kDa band mi-
grates in the same position as human recombinant bFGF.
Three species of bFGF have also been detected in human
mammary cell lines (18, 24 and 27 kDa) [10], the expression
of the 18-kDa species in cell lines having an epithelial mor-
phology and the 24- and 26-kDa bands in myoepithelial-like
cells [35]. Although preabsorption of the bFGF antibody with
bFGF was shown to be speci¢c, our data do not discard that
the 26- and 45-kDa proteins are not related to bFGF. The
highest and lowest levels of the 18-kDa bFGF species were
detected by immuno-Western blot in pregnant and lactating
mammary tissue, respectively. These data correlated well with
bFGF content assessed by RIA (Table 5) and our immuno-
cytochemistry studies (data not shown).
It has previously been shown that bFGF increases the num-
ber of MMEC from virgin animals [19]. We have now con-
¢rmed these observations, extended them to cells from ani-
mals at di¡erent stages of mammary development and
examined the e¡ects on milk protein synthesis in cells cultured
in a two-step culture system that simulates the physiological
process. Both EGF and bFGF increase proliferation, but the
e¡ect of bFGF was greater in cells from pregnant animals.
This corresponded both with the increased level of bFGF and
its receptors in the mammary tissue in vivo. The bFGF re-
ceptors were detectable by the binding of [125I]bFGF to
MMEC in agreement with one study reported previously
[34] in which only high a⁄nity [125I]bFGF binding sites on
rat ¢broblastic and myoepithelial-like cell lines were detected
but not on mammary epithelial cell lines [36]. Priming of
MMEC with bFGF and/or insulin, followed by induction
with the lactogenic hormones, greatly increased the synthesis
of milk proteins. Expression of the milk protein genes was
also increased. The di¡erence between the increase of milk
protein (3-fold) and mRNA (10-fold) is noteworthy. It is pos-
sible that posttranscriptional control may play a role in addi-
tion to the transcriptional regulation. The additive nature of
the responses to a mixture of the two factors indicates di¡er-
ences in the mode of action of bFGF and insulin. Basic FGF
resembles EGF in inhibiting the precocious functional di¡er-
entiation evidenced by the synthesis of casein and its corre-
sponding mRNA.
It has recently been shown that the expression of a domi-
nant-negative FGF receptor isoform in the mammary epithe-
lium of transgenic mice caused a marked impairment of lobu-
lo-alveolar development [36]; the growth retardation was
apparent in mid-pregnancy and persisted in the post-partum
mammary glands. Despite the substantial underdevelopment
of the mammary tissue there was a measurable lactational
response, but it was insu⁄cient to properly sustain the new-
born pups. These ¢ndings demonstrate that FGF signaling
was necessary for pregnancy dependent lobulo-alveolar devel-
opment of the mammary gland [37].
Our MMEC culture may presumably contain both epithe-
lial and myoepithelial cells which could be important to data
interpretation due to the fact that myoepithelial cells can pro-
duce FGF and/or present FGF receptors. Myoepithelial cells
are most abundant in the lactating gland in which they may
comprise roughly 10^20% at best. These cells are much less in
pregnant and virgin glands. With regard to this point our
results showed: ¢rst, MMEC obtained from pregnant mam-
mary tissue comprise 95% of the total population; and sec-
ond, the e¡ect of bFGF is most prominent in mammary cells
from pregnant mammary gland. This makes it very unlikely
that the e¡ect of FGF takes place on myoepithelial cells ^ if
this is the case, we should see the biggest e¡ect of FGF on the
cells from lactating mammary tissue.
Our data provide evidence of the existence of an autocrine
and or paracrine regulatory loop for FGF in the mouse mam-
mary epithelial cells. This is supported by the fact that bFGF
appears to be produced by the MMEC. Although the quanti-
tation of bFGF content was done in the mammary tissue, our
immunocytochemical studies showed that bFGF and aFGF
were mainly found in the MMEC and myoepithelial cells,
respectively. High a⁄nity FGF receptors were detected in
MMEC which could be activated by bFGF or aFGF.
bFGF is able to activate FGF receptor. Third, the biological
e¡ects of bFGF ([3H]thymidine and 3H-amino acid incorpo-
rations, milk gene expression) also take place in the MMEC.
In summary, our data showed that bFGF is present in the
mouse mammary tissue and that the content of bFGF and its
receptors in mammary tissue changes markedly during the
di¡erent physiological stages of development. bFGF not
only stimulates growth but has also an inhibitory e¡ect on
functional di¡erentiation of MMEC. As such, bFGF may
be added to the growing list of putative regulatory growth
factors known to modulate development of mammary epithe-
lial cells.
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